The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review.

Carcinoma, Transitional Cell / pathology Humans Radiotherapy, Adjuvant / methods Survival Analysis Urologic Neoplasms / pathology
Adjuvant radiotherapy Bladder cancer Recurrence Upper tract urothelial carcinoma

Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
10 2019
Historique:
received: 08 03 2019
revised: 23 05 2019
accepted: 29 05 2019
pubmed: 1 7 2019
medline: 17 9 2020
entrez: 1 7 2019
Statut: ppublish

Résumé

The role of adjuvant radiotherapy (ART) in patients with bladder cancer (BCa) and upper tract urothelial carcinoma (UTUC) is controversial. We systematically evaluated the oncologic efficacy of ART and its associated toxicity in patients treated with surgery and ART for BCa and UTUC. We performed a literature search on December 2018 using MEDLINE, Web of Science, Cochrane databases and Scopus according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Fourteen BCa studies and 14 UTUC studies were included in this systematic review. The data were too scarce and heterogeneous for meta-analytical analysis. The quality and quantity of the data on ART in BCa and UTUC patients are limited. The combination of ART and chemotherapy appears to be beneficial in patients with locally advanced BCa or UTUC. The early and late adverse effects of ART are decreasing reflecting the progress in radiation technology. According to the currently available literature, there is no clear benefit of ART after radical surgery in BCa and UTUC. Future efforts should focus on evaluating multimodal approach using ART with chemotherapy. Until that time comes, ART should be used carefully in patients with BCa and UTUC on a case-by-case basis.

Identifiants

DOI: 10.1016/j.urolonc.2019.05.021 PMID: 31255542
pubmed: 31255542
pii: S1078-1439(19)30221-2
doi: 10.1016/j.urolonc.2019.05.021
pii:
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

659-671

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Takehiro Iwata (T)

Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Shoji Kimura (S)

Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Jikei University School of Medicine, Tokyo, Japan.

Mohammad Abufaraj (M)

Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan.

Florian Janisch (F)

Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Pierre I Karakiewicz (PI)

Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Québec, Canada.

Veronika Seebacher (V)

Department for Gynaecology and Gynaecologic Oncology, Medical University of Vienna, Vienna, Austria.

Morgan Rouprêt (M)

Department of Urology, Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France.

Yasutomo Nasu (Y)

Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

Shahrokh F Shariat (SF)

Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. Electronic address: shahrokh.shariat@meduniwien.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Carcinomes › Carcinome transitionnel › The role of adjuvant radiotherapy after...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The role of adjuvant radiotherapy after...
questionsmedicales.fr › Thérapeutique › Radiothérapie › Radiothérapie adjuvante › The role of adjuvant radiotherapy after...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › The role of adjuvant radiotherapy after...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › The role of adjuvant radiotherapy after...